Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | SR9009; Stenabolic | Nickname is not a chemical name. |
| Typical analytical method | LC-MS/MS | Often with isotope-labeled internal standard. |
| Storage temperature | -20 °C | Desiccated and protected from light. |
| Solution stability | DMSO stock; avoid freeze-thaw | Store at -20 to -80 °C. |
| Regulatory status | Not approved; varies by country | May be restricted as research chemical. |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
== Arsenic poisoning treatment == There are three molecules that serve as chelator agents that bond to arsenic. These three are British Anti-Lewisite (BAL; dimercaprol), succimer (dimercaptosuccinic acid; DMSA) and Unithiol (2,3-dimercapto-1-propanesulfonic acid; DMPS). When these agents chelate inorganic arsenic, it is converted into an organic form of arsenic because it is bound to the organic chelating agent. The sulfur atoms of the thiol groups are the site of interaction with arsenic. This is because the thiol groups are nucleophilic while the arsenic atoms are electrophilic. Once bound to the chelating agent the molecules can be excreted, and therefore free inorganic arsenic atoms are removed from the body. Other chelating agents can be used, but may cause more side effects than British Anti-Lewisite (BAL, Dimercaprol), succimer (DMSA) and (DMPS). DMPS and DMSA also have a higher therapeutic index than BAL. These drugs are efficient for acute poisoning of arsenic, which refers to the instantaneous effects caused by arsenic poisoning. For example, headaches, vomiting or sweating are some of the common examples of an instantaneous effect. In comparison, chronic poisonous effects arise later on, and unexpectedly such as organ damage. Usually it is too late to prevent them once they appear. Therefore, action should be taken as soon as acute poisonous effects arise.
Some unicellular algae have become heterotrophs or parasites, relying entirely on external energy sources. Algae have photosynthetic machinery ultimately derived from cyanobacteria that produce oxygen by splitting water molecules, unlike photosynthetic bacteria. Fossilized filamentous algae from the Vindhya basin have been dated to 1.6 to 1.7 billion years ago. Because of the wide range of types of algae, there is a correspondingly wide range of industrial and traditional applications in human society. Traditional seaweed farming practices have existed for thousands of years and have strong traditions in East Asian food cultures. More modern algaculture applications extend the food traditions for other applications, including cattle feed, using algae for bioremediation or pollution control, transforming sunlight into algae fuels or other chemicals used in industrial processes, and in medical and scientific applications.
Involuntarily, I compare the mummified sovereign—now small and weathered—to the giant man I saw in 1886 entering the See of São Paulo. Amidst a colossal wave of people, he dominated the crowd, appearing many cubits taller. The body of Pedro II and that of his wife Teresa Cristina (who was also embalmed) were officially repatriated to Brazil aboard a Brazilian Navy ship in 1921. The emperor and empress are now interred in the Imperial Mausoleum within the Cathedral of Saint Peter of Alcantara in Petrópolis, a city founded by Pedro II himself.
The term diabetes is derived from the Ionic for 'siphon', meaning "to pass or run through". It reflects the dominant notion at the time that fluids consumed by the diabetic patient passed through the body unchanged, as if flowing through a tube or siphon. A number of conflicting accounts exist as to the first use of this term, placing the originator as either Apollonius of Memphis (fl. 3rd century BC), Demetrius of Apamea (fl. 100 BC), or Aretaeus of Cappadocia (fl. early 2nd century AD). In-depth probes of Greek etymology agree that the term came from Demetrius of Apamea, C. L. Gemmill (1972) states:Caelius Aurelianus prepared a Latin version of the works of Soranus. In the index of the Drabkin edition there is a subject heading "Diabetes," but on examination of the text this section could not be found (footnote 3, p. 776) except for a short paragraph. In this paragraph Caelius quotes Apollonius of Memphis as separating two forms of dropsy, one marked by retention of fluid and the other by the inability to retain fluid; the patient discharges whatever he drinks as if it were passed through a pipe. Apollonius lived in the second half of the third century B.C. Caelius Aurelianus continues by stating that Demetrius of Apamea distinguishes this disease from dropsy in which any fluid that is drunk is discharged as urine. Demetrius calls this condition diabetes. The time of Demetrius of Apamea is given as the first century B.C. None of his works have come down to us; we have only quotations in later authors.
Sources: en.wikipedia.org
The mechanism of antibody production in Sjögren's syndrome is not fully understood, but apoptosis (programmed cell death) and molecular mimicry may play a role. The Ro and La antigens are expressed on the surface of cells undergoing apoptosis and may cause the inflammation within the salivary gland by interaction with cells of the immune system. The antibodies may also be produced through molecular mimicry, where cross reactive antibodies bind to both virus and human proteins. This may occur with one of the antigens, Ro or La, and may subsequently produce antibodies to other proteins through a process known as epitope spreading. The retroviral gag protein shows similarity to the La protein and is proposed as a possible example for molecular mimicry in Sjögren's syndrome.
Most remaining forest is found inside reserves and national parks. Habitat destruction has proved a threat for marine life. Illegal fishing is another major threat, with fishing methods such as dynamite fishing and poisoning depleting marine ecosystems. Leatherback turtle numbers have dropped by 98% since the 1950s. Hunting has also been an issue for some animals, with overconsumption and the use of animal parts for profit endangering many animals, from marine life to tigers. Marine life is also detrimentally affected by uncontrolled tourism. The Malaysian government aims to balance economic growth with environmental protection, but has been accused of favouring big business over the environment. Some state governments are now trying to counter the environmental impact and pollution created by deforestation; and the federal government is trying to cut logging by 10% each year. A total of 28 national parks have been established, 23 in East Malaysia and five in the peninsula. Tourism has been limited in biodiverse areas such as the island of Sipadan. Wildlife trafficking is a large issue, and the Malaysian government has held talks with the governments of Brunei and Indonesia to standardise anti-trafficking laws.
== Effects and symptoms == Hemoglobin in combination with normal hemoglobin (heterozygous HBD/HbA) is asymptomatic, causing no effects. Individuals have normal hemoglobin level and their red blood cells are normal spherical structure. Homozygous HbD/HbD causes mild hemolytic anemia and chronic non-progressive splenomegaly (enlargement of spleen). Heterozygous HbD/HbS causes sickle cell anemia. However, most cases of the disease are milder than the usual HbS/HbS conditions. The most serious complication noted is stroke. HbD-thalassemia causes microcytic anemia which is generally milder that in typical thalassemia.
Sources: en.wikipedia.org
The concept of hospital as institution to offer medical care and possibility of a cure for the patients due to the ideals of Christian charity, rather than just merely a place to die, appeared in the Byzantine Empire. Although the concept of uroscopy was known to Galen, he did not see the importance of using it to localize the disease. It was under the Byzantines with physicians such of Theophilus Protospatharius that they realized the potential in uroscopy to determine disease in a time when no microscope or stethoscope existed. That practice eventually spread to the rest of Europe. After 750 CE, the Muslim world had the works of Hippocrates, Galen and Sushruta translated into Arabic, and Islamic physicians engaged in some significant medical research. Notable Islamic medical pioneers include the Persian polymath, Avicenna, who, along with Imhotep and Hippocrates, has also been called the "father of medicine". He wrote The Canon of Medicine which became a standard medical text at many medieval European universities, considered one of the most famous books in the history of medicine. Others include Abulcasis, Avenzoar, Ibn al-Nafis, and Averroes. Persian physician Rhazes was one of the first to question the Greek theory of humorism, which nevertheless remained influential in both medieval Western and medieval Islamic medicine. Some volumes of Rhazes's work Al-Mansuri, namely "On Surgery" and "A General Book on Therapy", became part of the medical curriculum in European universities.
=== Early life, start of career and Basel === Photaki was born in Corinth in 1921 and finished her secondary education at the 2nd Girls' Gymnasium of Athens in 1938. In the same year she enrolled at the Department of Chemistry in the University of Athens, where she specialised in Organic chemistry under the mentorship of Leonidas Zervas. Her studies were interrupted during the Axis occupation of Greece when the Laboratory of Organic Chemistry was destroyed and Zervas was imprisoned as a member of the Greek Resistance. Photaki was finally awarded her degree summa cum laude in 1946 and subsequently continued her postgraduate studies under Zervas, earning her PhD in 1950 with a dissertation regarding glucosamine. Concurrently, she held a paid laboratory assistant position at the university already from 1943, carrying on as a research assistant until 1953. In 1953, Photaki was awarded a scholarship to conduct research in Basel after examinations by the Greek State Scholarships Foundation. At the University of Basel she worked in the Laboratory of Organic Chemistry, at the time headed by Nobel laureate Tadeusz Reichstein. For the first two years of her stay (1953–1955) she was part of the Max Brenner research group, later moving as an independent scientific associate of Hans Erlenmeyer. Upon returning to Greece, she initially worked at the biochemical lab of the Evangelismos Hospital before being invited by Zervas to the nascent National Hellenic Research Foundation (NHRF) which he had helped found.
== Artificial cartilage == Synthetic cartilage can be composed of many different materials that mimic its functional properties. Tissue engineering principles include the use of cells, growth factors, and synthetic scaffolds in order to do this.
Osteoblasts (from the Greek combining forms for "bone", ὀστέο-, osteo- and βλαστάνω, blastanō "germinate") are cells with a single nucleus that synthesize bone. However, in the process of bone formation, osteoblasts function in groups of connected cells. Individual cells cannot make bone. A group of organized osteoblasts together with the bone made by a unit of cells is usually called the osteon. Osteoblasts are specialized, terminally differentiated products of mesenchymal stem cells. They synthesize dense, crosslinked collagen and specialized proteins in much smaller quantities, including osteocalcin and osteopontin, which compose the organic matrix of bone. In organized groups of disconnected cells, osteoblasts produce hydroxyapatite, the bone mineral, that is deposited in a highly regulated manner, into the inorganic matrix forming a strong and dense mineralized tissue, the mineralized matrix. Hydroxyapatite-coated bone implants often perform better as those not coated with this material. For instance, in patients with fatty liver disease hydroxyapatite-coated titanium implants perform better as those not-coated with this material. The mineralized skeleton is the main support for the bodies of air breathing vertebrates. It is also an important store of minerals for physiological homeostasis including both acid–base balance and calcium or phosphate maintenance.
Sources: en.wikipedia.org
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.
Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.
Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.